首页> 外文期刊>Trials >Is there an interest in repeating the vaginal administration of dinoprostone (Propess?), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial
【24h】

Is there an interest in repeating the vaginal administration of dinoprostone (Propess?), to promote induction of labor of pregnant women at term? (RE-DINO): study protocol for a randomized controlled trial

机译:是否有兴趣重复Dinoprostore(Preavess?)的阴道施用,以促进孕妇患者的植入术语? (RE-DINO):随机对照试验的研究方案

获取原文
           

摘要

BACKGROUND:Labor is induced in over 20% of women in France. Prostaglandins, especially intravaginal dinoprostone (Propess?), are widely used to initiate cervical ripening. If labor does not start within 24?h, there is uncertainty about whether to administer a second dinoprostone pessary or to use oxytocin to induce labor in order to achieve a vaginal delivery.METHODS:RE-DINO is a prospective, open-label, multicenter, randomized superiority trial with two parallel arms running in six French hospitals. A total of 360 patients ≥ 18?years of age at ?37?weeks of gestation who exhibit unfavorable cervical conditions (Bishop score??6) 24?h after placement of the first Propess?, with fetuses in cephalic presentation, will be included. Patients with premature membrane rupture, uterine scars, or multiple pregnancies will be excluded. Our principal objective is to determine whether placement of a second Propess? (followed by oxytocin [Syntocinon?], if necessary) in women for whom the first Propess? failed to induce cervical ripening increases the vaginal delivery rate compared to direct oxytocin injection. The vaginal delivery rate is therefore the primary outcome. The secondary outcomes are the induction failure rates and maternofetal morbidity and mortality.DISCUSSION:This study may help in determining the optimal way to induce labor after failure of a first Propess?, an unresolved problem to date. This trial explores the effectiveness and safety of placing a second Propess? and may contribute to development of an obstetric consensus.TRIAL REGISTRATION:Registered on 2 September 2016 at clinicaltrials.gov (identification number NCT02888041).
机译:背景:劳动力在法国超过20%的妇女诱导。前列腺素,尤其是静脉内含吲哚酮(Preavess?),广泛用于引发宫颈成熟。如果劳动力不在24?h内开始,则是否有关于施用第二个Dinoprostore细胞腔或使用催产素诱导劳动力以实现阴道递送的不确定性。方法:Re-Dino是一个未来的,开放标签的多中心,随机优势试验与六家法国医院运行的两个平行武器。共有360名患者≥18?岁月> 37?37?几周的妊娠,其表现出不利的宫颈状况(主教得分?<?6)24?H放置第一个Preavess之后?,在头部呈现的胎儿中,将包括在内。患有过早的膜破裂,子宫疤痕或多重妊娠的患者将被排除在外。我们的主要目标是确定是否有第二步的展示? (随后是催产素[Syntocinon?],如有必要)在谁是第一个谁?与直接催产素注射相比,未能诱导宫颈成熟增加阴道输送率。因此,阴道递送率是主要的结果。二次结果是感应失败率和母体发病率和死亡率。探讨:本研究可能有助于确定在第一个特权失败后诱导劳动力的最佳方式?,到目前为止尚未解决的问题。该试验探讨了第二个特权的有效性和安全性吗?并可能有助于发展产科共识.TRIAL注册:2016年9月2日在Clinicaltrials.gov注册(识别号NCT02888041)。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号